General Factor Bethesda Units, Plasma
Use
This test is useful for detecting and quantifying the presence and titer of a specific factor inhibitor directed against a specific coagulation factor. The presence of a coagulation factor inhibitor can result in significant and potentially life-threatening bleeding, and it is crucial to assess the inhibitor's presence for appropriate treatment management. The test uses Bethesda units as a standardized measure to define the inhibitor titer, which can guide the treatment approach whether the inhibitor is due to hemophilia or of an acquired nature.
Special Instructions
The test is only orderable as a reflex through specified profiles like Bleeding Diathesis Profile Limited, Comprehensive, or specific Factor Inhibitor Evaluation profiles. It cannot be ordered independently.
Limitations
This test may be affected by improper specimen collection and handling, such as gross hemolysis, lipemia, or icterus, which can lead to specimen rejection and affect test results. The test's performance characteristics have been determined by Mayo Clinic but have not been cleared or approved by the FDA. Factors measured include both undiluted and serially diluted patient plasma compared against a standard control to determine factor activity loss.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 13591-3
- 13591-3
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |